KRYS — Krystal Biotech Income Statement
0.000.00%
Last trade - 00:00- $7.63bn
- $6.80bn
- $389.13m
Annual income statement for Krystal Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 50.7 | 291 | 389 |
| Cost of Revenue | |||||
| Gross Profit | — | — | 47.6 | 270 | 366 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 68.3 | 145 | 60.4 | 225 | 228 |
| Operating Profit | -68.3 | -145 | -9.73 | 65.7 | 161 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -69.6 | -140 | 12.9 | 95.4 | 189 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -69.6 | -140 | 10.9 | 89.2 | 205 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -69.6 | -140 | 10.9 | 89.2 | 205 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -69.6 | -140 | 10.9 | 89.2 | 205 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.13 | -4.51 | -1.66 | 4.18 | 6.84 |